Search

Your search keyword '"Rotzinger, Susan"' showing total 418 results

Search Constraints

Start Over You searched for: Author "Rotzinger, Susan" Remove constraint Author: "Rotzinger, Susan"
418 results on '"Rotzinger, Susan"'

Search Results

1. Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression study

2. Endocannabinoid concentrations in major depression: effects of childhood maltreatment and relation to hippocampal volume

3. Publisher Correction: Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo

4. Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo

5. AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale

6. Depression-Anxiety Coupling Strength as a predictor of relapse in major depressive disorder: A CAN-BIND wellness monitoring study report

7. Atypical Brain Aging and Its Association With Working Memory Performance in Major Depressive Disorder

9. A standardized workflow for long-term longitudinal actigraphy data processing using one year of continuous actigraphy from the CAN-BIND Wellness Monitoring Study

11. An empirical analysis of structural neuroimaging profiles in a staging model of depression

12. Relation of hippocampal volume and SGK1 gene expression to treatment remission in major depression is moderated by childhood maltreatment: A CAN-BIND-1 report

16. Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study

17. Alterations in the neural correlates of affective inhibitory control following cognitive behavioral therapy for depression: A Canadian biomarker integration network for depression (CAN-BIND) study

20. Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study

24. Atypical brain aging and its association with working memory performance in major depressive disorder

25. Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report

27. White matter microstructure in youth at risk for serious mental illness: A comparative analysis

28. Atypical Brain Aging and Its Association With Working Memory Performance in Major Depressive Disorder

31. Functional neuroimaging biomarkers of anhedonia response to escitalopram plus adjunct aripiprazole treatment for major depressive disorder

34. Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report

35. Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report

36. Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report

38. Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response

39. Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study

40. Anxious arousal predicts within-person changes in hippocampal volume in adults with a history of childhood maltreatment: A CAN-BIND4 report.

41. Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication

43. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study

44. The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols

45. Influence of CYP2C19, CYP2D6, and ABCB1Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study

46. GPR56/ADGRG1 is associated with response to antidepressant treatment

47. Pro-inflammatory markers are associated with response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report

48. 286. Genetic Polymorphism of Brain-Derived Neurotrophic Factor is Related to Antidepressant Efficacy and Treatment-Induced Hippocampal Plasticity in Patients With Major Depressive Disorder: CAN-BIND-1 Study

49. AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale.

50. AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder:COORDINATE-MDD consortium design and rationale

Catalog

Books, media, physical & digital resources